CD34+ HSC-derived modified/manipulated DCs have also been clinically investigated in cancer settings with promising outcomes, such as generation of tumor-specific immunity and/or induction of tumor regression in patients with metastatic melanoma (92, 93). Here, CD34 is linked to neoplasm.